Results 271 to 280 of about 108,133 (341)

Semaglutide versus caloric restriction‐induced weight loss: insights into effects on skeletal muscle mass and function

The Journal of Physiology, EarlyView.
Harsh Shah, Julio E. Ayala
wiley   +1 more source

Integrated Genetic and Protein Mechanisms Underlying Glucagon-like Peptide-1 Receptor Agonists in Treating Diabetes Mellitus and Weight Loss. [PDF]

Curr Issues Mol Biol
Francis L, Butler MG.
europepmc   +1 more source

Shortages of benzathine benzylpenicillin G in Australia highlight the need for new sovereign manufacturing capability

Medical Journal of Australia, Volume 222, Issue 5, Page 223-225, March 2025.
Rosemary Wyber, Glenn Pearson, Laurens Manning   +2 more
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists and Pay-Per-Click Direct-to-Consumer Advertising.

JAMA Netw Open
Eisenkraft Klein D, Zenone M, Kesselheim AS.   +2 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Glucagon-like Peptide-1 Receptor Agonists

Stroke Revisited, 2021
Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) have been used to treat patients with type 2 diabetes mellitus (T2DM) since exenatide, the first GLP-1RA, was approved in 2005. GLP-1 is a peptide hormone secreted by L cells of the small intestine in response to nutrients.
J. Jeon, H. Kim
semanticscholar   +2 more sources

Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists.

JAMA
This Viewpoint discusses the health benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs); summarizes the clinical, policy, and equity implications of GLP-1 RA discontinuation; and calls for the identification and implementation of ...
Sadiya S Khan, C. Ndumele, Dhruv S. Kazi
semanticscholar   +3 more sources

Glucagon-like peptide-1 receptor agonists

, 2016
Native glucagon-like peptide-1 (GLP-1) is not practical for therapeutic use due to a short half-life caused by ubiquitous, fast, and effective in vivo degradation by the enzyme dipeptidyl peptidase-4 (DPP-4).
B. Gallwitz
semanticscholar   +2 more sources

Effect of glucagon‐like peptide‐1 receptor agonists on body weight in adults with obesity without diabetes mellitus—a systematic review and meta‐analysis of randomized control trials

Obesity Reviews, 2022
Clinical trials have investigated the weight loss effect of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) in adults with obesity without diabetes mellitus, but results for weight loss efficacy were varied.
Junaid Iqbal, Hui-Xuan Wu, Nan Hu, Ying-Hui Zhou, Long Li, Fen Xiao, Ting Wang, Hong-Li Jiang, Shi-Na Xu, Bi-Ling Huang, Houde Zhou   +10 more
semanticscholar   +1 more source